D. Holyoake

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. M. Hawkins · 8 shared papers, 2016–2026 · strength 0.98
   • Paper Corrigendum to "SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pa… DOI 10.1016/j.radonc.2026.111610↗
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. DOI 10.1016/j.radonc.2020.11.007↗
2. Ganesh Radhakrishna · 7 shared papers, 2016–2026 · strength 0.89
   • Paper Corrigendum to "SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pa… DOI 10.1016/j.radonc.2026.111610↗
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. DOI 10.1016/j.radonc.2020.11.007↗
3. Derek B. Grose · 6 shared papers, 2016–2026 · strength 0.74
   • Paper Corrigendum to "SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pa… DOI 10.1016/j.radonc.2026.111610↗
   • Paper SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. DOI 10.1016/j.radonc.2020.11.007↗
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
4. Somnath Mukherjee · 7 shared papers, 2016–2024 · strength 0.68
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. DOI 10.1016/j.radonc.2020.11.007↗
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
5. Christopher Mark Jones · 3 shared papers, 2020–2024 · strength 0.35
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
   • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
6. Pippa G. Corrie · 3 shared papers, 2020–2024 · strength 0.35
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
   • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
7. Chris N Hurt · 2 shared papers, 2018–2024 · strength 0.25
   • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
   • Paper Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cance… DOI 10.1016/j.clon.2018.02.067↗
8. James S. Good · 2 shared papers, 2020–2021 · strength 0.19
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
   • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
9. Paula Ghaneh · 2 shared papers, 2020–2021 · strength 0.19
   • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
   • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
10. Katharine L. Aitken · 2 shared papers, 2020–2021 · strength 0.19
    • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
    • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
11. Daniel H. Palmer · 2 shared papers, 2020–2021 · strength 0.19
    • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
    • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
12. Nigel Balfour Jamieson · 2 shared papers, 2020–2021 · strength 0.19
    • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
    • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
13. Juan W. Valle · 2 shared papers, 2020–2021 · strength 0.19
    • Paper Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". DOI 10.1038/s41416-020-01133-8↗
    • Paper Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. DOI 10.1038/s41416-020-0980-x↗
14. Tim Maughan · 1 shared paper, 2024 · strength 0.16
    • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
15. Thankamma Ajithkumar · 1 shared paper, 2024 · strength 0.16
    • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
16. Harpreet Singh Wasan · 1 shared paper, 2024 · strength 0.16
    • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
17. Eric E. O’Neill · 1 shared paper, 2024 · strength 0.16
    • Paper Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally ad… DOI 10.1016/j.ejca.2024.114236↗
18. Mike Partridge · 2 shared papers, 2016–2018 · strength 0.15
    • Paper Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cance… DOI 10.1016/j.clon.2018.02.067↗
    • Paper Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for b… DOI 10.1016/j.radonc.2016.08.001↗
19. Victoria Y. Strauss · 1 shared paper, 2016 · strength 0.05
    • Paper A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPA… DOI 10.1186/s12885-016-2765-4↗
20. Emmanouil Fokas Fokas · 1 shared paper, 2016 · strength 0.05
    • Paper A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPA… DOI 10.1186/s12885-016-2765-4↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.